Evidence map›Paper›PMID 41004338›Full record

ArticleCell reports2025

Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state.

Mary C Rominger, Siobhan O'Brien, Saksham Gupta, Sitapriya Moorthi, Maria McSharry, Shriya Kamlapurkar, Amy R Lowe, Annie Waldum, April Lo, Fujiko Duke and 6 more

Abstract read
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Mary C RomingerHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Siobhan O'BrienHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Saksham GuptaHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Sitapriya MoorthiHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Maria McSharryHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Shriya KamlapurkarHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Amy R LoweHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Annie WaldumHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
April LoHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Fujiko DukeCancer Program, Broad Institute of MIT & Harvard, Cambridge, MA 02142, USA.
Feinan WuBioinformatics Shared Resource, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Mark B HeadleyTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Elizabeth CromwellPre-clinical Modeling Core, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Raisa GlabmanComparative Pathology, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Amanda KoehneComparative Pathology, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Alice H BergerHuman Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Herbold Computational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA. Electronic address: ahberger@fredhutch.org.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Project 4: Risk stratification for pulmonary nodules detected by CT imaging using plasma and imaging biomarkersP50CA228944 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PHILIP D GREENBERG · 2019 to 2026
$19.6M
Understanding and exploiting novel therapeutic vulnerabilities of RIT1-driven lung cancerR37CA252050 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Alice Berger · 2021 to 2026
$3.1M
Investigating the role of the small GTPase RIT1 in lung adenocarcinomaR00CA197762 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BERGER, ALICE · 2017 to 2019
$747k
Investigating the role of the small GTPase RIT1 in lung adenocarcinomaK99CA197762 · NCI · DANA-FARBER CANCER INST · PI BERGER, ALICE · 2015 to 2016
$156k
NCI NIH HHS K99 CA197762NCI NIH HHS P30 CA015704NCI NIH HHS P50 CA228944NCI NIH HHS R00 CA197762NCI NIH HHS R37 CA252050
6 · The paper itself

Abstract

Mutations in "Ras-like in all tissues" (RIT1) occur in up to 2% of lung adenocarcinomas and are mutually exclusive with KRAS and EGFR mutations, suggesting that RIT1 may act as a non-canonical driver oncogene in lung cancer. However, the lack of a RIT1-mutant lung cancer model has hindered the development and testing of RIT1-targeted therapeutics. Here, we report a mouse model with conditional regulation of the cancer-associated RIT1

Indexed as

Adaptor Proteins, Signal TransducingLung NeoplasmsMutationPhosphoproteinsras ProteinsTranscription FactorsAnimalsCell Cycle ProteinsHumansMiceTumor Suppressor Protein p53YAP-Signaling ProteinsAdaptor Proteins, Signal TransducingCell Cycle ProteinsPhosphoproteinsras ProteinsTranscription FactorsTumor Suppressor Protein p53Yap1 protein, mouseYAP-Signaling ProteinsAP-1CP: CancerEMTepithelial-to-mesenchymal transitionGEMMGTPaseHippolung cancerRASRIT1YAP

Identifiers

PMID41004338
PMCPMC12646131

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.